Skip to main content
logo
Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.150
-0.020 (-1.71%)
Sep 8, 2026, 12:02 PM EDT - Market open

Metagenomi Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
13.5625.2152.344.7617.20.24
Revenue Growth
-59.84%-51.79%16.84%160.21%6978.19%-
Gross Profit
-75.04-69.22-56.88-49.65-25.94-14.24
Operating Income
-100.57-96.01-88.9-78.49-44.64-23.95
Net Income
-93.46-87.87-78.06-68.26-43.59-21.44
Earnings Per Share
-2.49-2.36-2.36-20.05-12.82-3.77
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
120.66160.8248.31271.18362.13108.15
Total Debt
37.7240.6645.7848.2318.5748.93
Net Cash (Debt)
82.94120.14202.53222.95343.5659.23
Net Cash Growth
-48.80%-40.68%-9.16%-35.10%480.08%-
Net Cash Per Share
2.213.236.1365.49101.0610.41

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-85.49-88.89-109.07-91.4129.7224.26
Capital Expenditures
-0.31-0.57-3.11-9.81-13.98-2.9
Free Cash Flow
-85.8-89.47-112.19-101.2215.7521.35
Free Cash Flow Growth
-----26.26%-

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--274.58%-108.78%-110.93%-150.81%-
Operating Margin
-741.58%-380.85%-170.00%-175.38%-259.53%-9854.73%
Pretax Margin
-690.60%-348.77%-159.81%-134.57%-238.51%-8823.87%
Profit Margin
-689.20%-348.54%-149.27%-152.50%-253.45%-8823.87%
FCF Margin
-632.67%-354.88%-214.53%-226.17%91.55%8787.65%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
3.262.412.58---